Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

dc.contributor.authorFernández Santiago, Rubén
dc.contributor.authorMerkel, Angelika
dc.contributor.authorCastellano, Giancarlo
dc.contributor.authorHeath, Simon
dc.contributor.authorRaya Chamorro, Ángel
dc.contributor.authorTolosa, Eduardo
dc.contributor.authorMarti, Maria Jose
dc.contributor.authorConsiglio, Antonella
dc.contributor.authorEzquerra Trabalón, Mario
dc.date.accessioned2020-10-27T10:53:08Z
dc.date.available2020-10-27T10:53:08Z
dc.date.issued2019-07-23
dc.date.updated2020-10-27T10:53:08Z
dc.description.abstractBackground: Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec697533
dc.identifier.issn1868-7075
dc.identifier.pmid31337434
dc.identifier.urihttps://hdl.handle.net/2445/171541
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s13148-019-0701-6
dc.relation.ispartofClinical Epigenetics, 2019, vol. 11
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/311736/EU//PD-HUMMODEL
dc.relation.urihttps://doi.org/10.1186/s13148-019-0701-6
dc.rightscc-by (c) Fernández Santiago, Rubén et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationADN
dc.subject.classificationMetilació
dc.subject.otherParkinson's disease
dc.subject.otherDNA
dc.subject.otherMethylation
dc.titleWhole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
697533.pdf
Mida:
739.03 KB
Format:
Adobe Portable Document Format